2-(cyclohexylmethylidenehydrazino)adenosine , 97% , 144348-08-3
PRODUCT Properties
| Melting point: | 154-157° |
| Boiling point: | 765.6±70.0 °C(Predicted) |
| Density | 1.76 |
| storage temp. | Store at -20°C |
| solubility | DMSO : 125 mg/mL (319.35 mM; Need ultrasonic) |
| pka | 6.92±0.70(Predicted) |
| form | Solid |
| color | White to off-white |
| InChIKey | XJFMHMFFBSOEPR-XNIJJKJLSA-N |
| SMILES | OC[C@H]1O[C@@H](N2C3C(=C(N=C(NN=CC4CCCCC4)N=3)N)N=C2)[C@H](O)[C@@H]1O |
Description and Uses
Binodenoson, 2-[(cyclohexylmethylene)hydrazino] adenosine (MRE0470), is being developed as a short-acting coronary vasodilator, administered intravenously, as an adjunct to radiotracers in myocardial stress imaging techniques to detect the presence and severity of CAD in patients unable to exercise. The compound is a highly selective agonist at the adenosine A2A receptor and also has a weaker affinity for adenosine A1-, A2B-, and A3-receptor subtypes than adenosine[1].
2-(cyclohexylmethylidenehydrazino)adenosine is used in the diagnosis of coronary heart disease (adenosine A2A agonist).
